State “Mini-HSR” Laws Are Starting to Matter in Healthcare M&A

Monday, June 8th, 2026

For a long time, most M&A lawyers treated antitrust filing analysis as a federal issue. The basic question was whether the deal triggered a filing under the Hart-Scott-Rodino Act (“HSR”). If it did, the parties built the federal waiting period into the deal timeline. If it did not, the antitrust notice usually was not a major closing issue.

That analysis is getting a little more complicated.

A number of states are now adopting their own pre-closing notice laws. Some of these laws look a lot like a state-level version of HSR. In general, if the parties are already making a federal HSR filing and the deal has a sufficient connection to the state, they may also have to send a copy of that filing to the state attorney general. Washington and Colorado enacted broad premerger notification laws in 2025. California has adopted a similar law scheduled to take effect in 2027. These laws typically do not create a separate approval process, but they do provide state regulators with more information earlier in the deal process.

That last point is the one deal teams should pay attention to. Even when a state filing does not add a new waiting period, it can still affect the way a transaction is managed. State attorney general offices are getting earlier notice, more time to review the transaction, and a clearer path to ask questions if they believe the deal raises competitive concerns.

Healthcare deals deserve separate attention because many of the state laws in this area are not just copy-of-HSR laws. Several states have adopted healthcare-specific notice or review requirements that can apply even when the transaction is nowhere near the federal HSR thresholds. In other words, a lower-middle-market healthcare deal may avoid federal HSR review entirely and still have a state-level notice issue.

These “mini-HSR” laws vary from state to state. Some focus on hospitals and larger health systems. Others reach physician groups, provider organizations, payors, management services organizations, private equity-backed platforms, or changes of control. Illinois, Massachusetts, Oregon, Rhode Island, Indiana, Maine, New York, Connecticut, Washington, and California all have some form of healthcare transaction notice or review regime. The details are not uniform. Some laws require notice only. Others allow for a more substantive review. Oregon’s program, for example, focuses not just on competition but also on cost, access, health equity, and quality. Indiana requires advance notice for certain mergers or acquisitions involving an Indiana healthcare entity with total assets of at least $10 million. Maine’s newer law is notable for its specific attention to transactions involving private equity companies, hedge funds, and management services organizations.

For buyers and sellers, the main takeaway is practical: state notice issues need to be checked early. This is especially true for physician practice acquisitions, behavioral health deals, home health and hospice transactions, pharmacy deals, DME suppliers, dental platforms, and MSO arrangements. Those are exactly the types of transactions where the parties may assume antitrust filings are unlikely because the purchase price is not large enough to trigger federal HSR.

A missed state notice requirement can create problems late in the deal. It can affect closing conditions, outside dates, financing timelines, and communications with lenders, investors, and regulators. It can also create frustration for sellers who thought the deal was on a clear path to closing, only to learn that a state filing or review period was overlooked.

The point is not that these laws should stop deals from getting done. Most transactions can still be managed with good planning. But the state-law analysis should happen before the parties commit to an aggressive timeline in a letter of intent or purchase agreement.

Before signing, buyers and sellers should ask a few basic questions. Where does the target operate? Where does the buyer already have a platform? Is private equity involved? Is there an MSO structure? Are physician practices, licensed facilities, home health agencies, hospices, pharmacies, or other regulated providers involved? Has the state adopted a healthcare transaction notice law, a broad mini-HSR law, or both?

State merger review is no longer limited to large hospital deals. It is becoming part of ordinary M&A planning. Parties that spot these matters early are in a much better position to manage expectations and keep the transaction moving toward closing.

To learn more, connect with Tom A. Knapp for guidance on mergers and acquisitions, strategic transactions, and corporate matters. A shareholder in the corporate and transactions group at Brown & Fortunato, Tom represents buyers, sellers, private equity groups, and healthcare providers in transactions involving durable medical equipment companies, pharmacies, home health agencies, hospice companies, behavioral health providers, and other healthcare businesses. Reach out at 806-345-6344 or tknapp@bf-law.com to discuss how he can help support your transaction goals.

This article is for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. This article was prepared on a specific date, and the law may have changed since it was written. You should contact your attorney to obtain advice with respect to your specific legal issue and needs.